6WS5
Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT
This is a non-PDB format compatible entry.
Summary for 6WS5
Entry DOI | 10.2210/pdb6ws5/pdb |
Descriptor | DNA repair protein REV1, Mitotic spindle assembly checkpoint protein MAD2B, DNA polymerase zeta catalytic subunit, ... (5 entities in total) |
Functional Keywords | scaffold, complex, translesion synethesis, dna damage response, dna damage tolerance, protein binding, protein binding-transferase complex, protein binding/transferase |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 3 |
Total formula weight | 42994.44 |
Authors | McPherson, K.S.,Korzhnev, D.M. (deposition date: 2020-04-30, release date: 2020-12-23, Last modification date: 2023-10-18) |
Primary citation | McPherson, K.S.,Zaino, A.M.,Dash, R.C.,Rizzo, A.A.,Li, Y.,Hao, B.,Bezsonova, I.,Hadden, M.K.,Korzhnev, D.M. Structure-Based Drug Design of Phenazopyridine Derivatives as Inhibitors of Rev1 Interactions in Translesion Synthesis. Chemmedchem, 16:1126-1132, 2021 Cited by PubMed: 33314657DOI: 10.1002/cmdc.202000893 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.472 Å) |
Structure validation
Download full validation report